These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 30852420)

  • 21. Walking pathways with positive feedback loops reveal DNA methylation biomarkers of colorectal cancer.
    Kel A; Boyarskikh U; Stegmaier P; Leskov LS; Sokolov AV; Yevshin I; Mandrik N; Stelmashenko D; Koschmann J; Kel-Margoulis O; Krull M; Martínez-Cardús A; Moran S; Esteller M; Kolpakov F; Filipenko M; Wingender E
    BMC Bioinformatics; 2019 Apr; 20(Suppl 4):119. PubMed ID: 30999858
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Aberrant DNA Methylation in Colorectal Cancer: What Should We Target?
    Tse JWT; Jenkins LJ; Chionh F; Mariadason JM
    Trends Cancer; 2017 Oct; 3(10):698-712. PubMed ID: 28958388
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinicopathological significance and potential drug target of O6-methylguanine-DNA methyltransferase in colorectal cancer: a meta-analysis.
    Zheng CG; Jin C; Ye LC; Chen NZ; Chen ZJ
    Tumour Biol; 2015 Aug; 36(8):5839-48. PubMed ID: 25716203
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MGMT germline polymorphism is associated with somatic MGMT promoter methylation and gene silencing in colorectal cancer.
    Ogino S; Hazra A; Tranah GJ; Kirkner GJ; Kawasaki T; Nosho K; Ohnishi M; Suemoto Y; Meyerhardt JA; Hunter DJ; Fuchs CS
    Carcinogenesis; 2007 Sep; 28(9):1985-90. PubMed ID: 17621591
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prevalence of RAS mutations and individual variation patterns among patients with metastatic colorectal cancer: A pooled analysis of randomised controlled trials.
    Peeters M; Kafatos G; Taylor A; Gastanaga VM; Oliner KS; Hechmati G; Terwey JH; van Krieken JH
    Eur J Cancer; 2015 Sep; 51(13):1704-13. PubMed ID: 26049686
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Genetic and epigenetic variation in the DNMT3B and MTHFR genes and colorectal adenoma risk.
    Ho V; Ashbury JE; Taylor S; Vanner S; King WD
    Environ Mol Mutagen; 2016 May; 57(4):261-8. PubMed ID: 27062459
    [TBL] [Abstract][Full Text] [Related]  

  • 27. DNA Hypermethylation of SHISA3 in Colorectal Cancer: An Independent Predictor of Poor Prognosis.
    Tsai MH; Chen WC; Yu SL; Chen CC; Jao TM; Huang CY; Tzeng ST; Yen SJ; Yang YC
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1481-9. PubMed ID: 25968618
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical and molecular characterisation of hereditary and sporadic metastatic colorectal cancers harbouring microsatellite instability/DNA mismatch repair deficiency.
    Cohen R; Buhard O; Cervera P; Hain E; Dumont S; Bardier A; Bachet JB; Gornet JM; Lopez-Trabada D; Dumont S; Kaci R; Bertheau P; Renaud F; Bibeau F; Parc Y; Vernerey D; Duval A; Svrcek M; André T
    Eur J Cancer; 2017 Nov; 86():266-274. PubMed ID: 29055842
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Do mutations in DNMT3A/3B affect global DNA hypomethylation among benzene-exposed workers in Southeast China?: Effects of mutations in DNMT3A/3B on global DNA hypomethylation.
    Zhang GH; Lu Y; Ji BQ; Ren JC; Sun P; Ding S; Liao X; Liao K; Liu J; Cao J; Lan Q; Rothman N; Xia ZL
    Environ Mol Mutagen; 2017 Dec; 58(9):678-687. PubMed ID: 28945286
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A novel DNA methylation panel accurately detects colorectal cancer independently of molecular pathway.
    Freitas M; Ferreira F; Carvalho S; Silva F; Lopes P; Antunes L; Salta S; Diniz F; Santos LL; Videira JF; Henrique R; Jerónimo C
    J Transl Med; 2018 Feb; 16(1):45. PubMed ID: 29486770
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The study of methylation and single nucleotide polymorphisms of cancer-related genes in patients with early-stage ulcerative colitis.
    Chen HX; Yuan ZY; Wu KX; Liu C; Mao QD; He BG; Yuan H
    Scand J Gastroenterol; 2019 Apr; 54(4):427-431. PubMed ID: 31046486
    [No Abstract]   [Full Text] [Related]  

  • 32. Clinical Relevance of Plasma DNA Methylation in Colorectal Cancer Patients Identified by Using a Genome-Wide High-Resolution Array.
    Lin PC; Lin JK; Lin CH; Lin HH; Yang SH; Jiang JK; Chen WS; Chou CC; Tsai SF; Chang SC
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1419-27. PubMed ID: 25472652
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of efficacy and safety markers in a phase II study of metastatic colorectal cancer treated with aflibercept in the first-line setting.
    Lambrechts D; Thienpont B; Thuillier V; Sagaert X; Moisse M; Peuteman G; Pericay C; Folprecht G; Zalcberg J; Zilocchi C; Margherini E; Chiron M; Van Cutsem E
    Br J Cancer; 2015 Sep; 113(7):1027-34. PubMed ID: 26355232
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The impact of polyunsaturated fatty acids on DNA methylation and expression of DNMTs in human colorectal cancer cells.
    Sarabi MM; Naghibalhossaini F
    Biomed Pharmacother; 2018 May; 101():94-99. PubMed ID: 29477476
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of PON1 Gene Promoter DNA Methylation and Genetic Variations on the Clinical Outcomes of Dual Antiplatelet Therapy for Patients Undergoing Percutaneous Coronary Intervention.
    Lei HP; Yu XY; Wu H; Kang YH; Zhong WP; Cai LY; Zhang MZ; Chen JY; Mai LP; Ding QS; Yang M; Zhong SL
    Clin Pharmacokinet; 2018 Jul; 57(7):817-829. PubMed ID: 28875477
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Promoter methylation and Ile105val polymorphism of
    Nissar S; Sameer AS; Rasool R; Chowdri NA; Rashid F
    Indian J Cancer; 2019; 56(3):248-253. PubMed ID: 31389389
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Association of TET1 expression with colorectal cancer progression.
    Tian Y; Pan F; Sun X; Gan M; Lin A; Zhang D; Zhu Y; Lai M
    Scand J Gastroenterol; 2017 Mar; 52(3):312-320. PubMed ID: 27846738
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CHFR promoter methylation indicates poor prognosis in stage II microsatellite stable colorectal cancer.
    Cleven AH; Derks S; Draht MX; Smits KM; Melotte V; Van Neste L; Tournier B; Jooste V; Chapusot C; Weijenberg MP; Herman JG; de Bruïne AP; van Engeland M
    Clin Cancer Res; 2014 Jun; 20(12):3261-71. PubMed ID: 24928946
    [TBL] [Abstract][Full Text] [Related]  

  • 39. AGXT and ERCC2 polymorphisms are associated with clinical outcome in metastatic colorectal cancer patients treated with 5-FU/oxaliplatin.
    Kjersem JB; Thomsen M; Guren T; Hamfjord J; Carlsson G; Gustavsson B; Ikdahl T; Indrebø G; Pfeiffer P; Lingjærde O; Tveit KM; Wettergren Y; Kure EH
    Pharmacogenomics J; 2016 Jun; 16(3):272-9. PubMed ID: 26261061
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Methylation associated transcriptional repression of ELOVL5 in novel colorectal cancer cell lines.
    Boot A; Oosting J; van Eendenburg JDH; Kuppen PJK; Morreau H; van Wezel T
    PLoS One; 2017; 12(9):e0184900. PubMed ID: 28931069
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.